Definium Therapeutics opened lower at $34.05, compared with its previous close of $34.47. In the last trading session, the stock traded between $32.75 and $34.05. It showed a downward intraday trend.
An investment of $100 made 1 year ago in Definium Therapeutics is now worth
$ 214.46
Giving a profit of
$ 114.46 (114.46%)
Note: Past profits do not guarantee future returns.
Rating from 15 Analysts
Today's Change
$-1.49 (-4.31%)
Day High
$34.05
Day Low
$32.75
Day Open
$34.05
Prev Close
$34.47
Volume
9,82,488
1W Return
0.91%
1M Return
-6.33%
3M Return
-19.36%
6M Return
54.13%
1Y Return
114.46%
Market Cap ($ Mn)
4,516
PE Ratio
-
PB Ratio
5.99
PEG Ratio
-
ROE
-82.60%
ROCE
-73.92%
EPS (TTM)
$-1.18
1 Week
0.91%
1 Month
-6.33%
3 Months
-19.36%
6 Months
54.13%
9 Months
90.11%
RBC Capital raises Definium Therapeutics price target to $70
RBC Capital maintains Outperform rating on Definium Therapeutics. Price target raised from $66 to $70 by analyst Brian Abrahams.
2 days agoDefinium Therapeutics Q3FY26 net loss narrows to $51.0 million
Net loss narrowed to $51.0 million in Q3FY26 from $67.3 million in Q3FY25. Cash position stands at $1.05 billion, funding operations into 2030. FDA Breakthrough Therapy designation received for DT120 in MDD. Payer pricing corridor identified between $30,000 and $75,000 per treatment.
3 days agoJP Morgan initiates Definium Therapeutics with Overweight, $84 target
JP Morgan initiates coverage on Definium Therapeutics. Assigned an Overweight rating to the stock. Announced a price target of $84 per share.
1mo agoDefinium's DT120 Meets Primary Endpoint in Phase 3 GAD Trial
Panorama Phase 3 study met primary endpoint for DT120 in GAD with LS mean difference of -5.1 points vs placebo. Efficacy observed as early as Day 2 with effect size of d=0.64 and p<0.0001 significance. No new safety signals reported; 97% of participants met end-of-session criteria by hour 8 across Phase 3 trials. Marks third successful Phase 3 readout for DT120 ODT following Emerge and Voyage studies. Company plans Pre-NDA meeting in 4Q 2026 and NDA filing in 1H 2027.
1mo agoDefinium Therapeutics secures second FDA breakthrough designation for DT120
Definium Therapeutics receives second FDA Breakthrough Therapy designation for DT120 ODT. Indication is major depressive disorder (MDD), following prior GAD designation. Phase 3 Emerge study showed 8.1-point placebo-adjusted MADRS improvement at Week 6. Efficacy was durable through Week 12 with p<0.0001 statistical significance. MDD affects over 21 million U.S. adults with remission rates under one-third.
2mo agoDefinium Therapeutics grants 88,900 stock options to new hires
Definium Therapeutics granted 88,900 stock options to three new non-executive employees. Grants were approved by the Compensation Committee on August 28, 2026. Options vest over four years with 25% cliff vesting after one year. Awards comply with NASDAQ Rule 5635(c)(4) and the 2026 Inducement Plan.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 1 year ago in Definium Therapeutics is now worth
$ 214.46
Giving a profit of
$ 114.46 (114.46%)
Note: Past profits do not guarantee future returns.
